Are you a patient?
Please visit our patient website for more information on cataract treatment:
You are on our international English website. This site features our entire product portfolio worldwide. The products featured may not be available in the US. If you are a citizen from the US, please visit your country website for local information and contacts.
In 2019, Dr. Pablo Luis Daponte was implanted with ZEISS AT LISA tri. As someone who enjoys outdoor activities and water sports, Dr. Daponte was determined to find a solution that would allow him to continue pursuing his profession and passions without limitations.
President (2010-Present) of the Italian Society of Ophthalmology, Dr. Matteo Piovella, has implanted the first AT LISA tri to his patients in 2012. Two years later, after witnessing the successful visual outcomes derived from the trifocal IOL, he decided to have the same surgery himself and have AT LISA tri implanted in his own eyes. Watch the video to know which aspects of his personal and professional life changed for the best after the surgery.
Dr. Frank Kerkhoff – Cataract, refractive and vitreoretinal surgeon from FYEO Medical - on the advantage of the Day 1 visual experience with ZEISS AT LISA tri and how this contributes to the long-term patient satisfaction.
Dr. Zhang Shunhua - Cataract surgeon from the Peking Union Medical College Hospital - on her experience in implanting ZEISS AT LISA tri and how realizing the vision dreams of her patients became a priority and a mission in her daily work.
Dr. Durval - Cataract and Glaucoma surgeon and vice president of the Brazilian Cataract and Refractive Surgery Association - on the patients´ post-operative success stories and visual long-term performance of ZEISS AT LISA tri.
Having implanted 20,000 ZEISS AT LISA tri IOLs himself, Dr. Jørn S. Jørgensen, Chairman, CEO and Founder of EuroEyes International, shares his long-standing expertise on IOL surgery and patient consultation.
This peer-reviewed publication is the longest study, reviewing Long-Term Efficacy, Visual Performance and Patient Reported Outcomes with Trifocal Intraocular Lenses.
AT LISA® tri family from ZEISS has repeatedly been the focus of scientific investigations when evaluating the performance of presbyopia-correcting IOLs. It has become the reference trifocal IOL, having been featured in numerous comparative analyses with other trifocal IOLs. Throughout these investigations, ZEISS AT LISA tri family has continually confirmed their excellent performance.
Outcomes from more than 4,500 patients implanted with ZEISS AT LISA tri family have already been analyzed in peer-reviewed articles. In evaluating these patient outcomes, surgeons have overwhelmingly discovered the same thing over and over again: high satisfaction and excellent visual outcomes. Thanks to this high predictability, you are able to constantly deliver optimal patient care.
Proven results and high patient satisfaction of the ZEISS AT LISA tri family are not confined to one region. Rather, outstanding results of peer-reviewed studies have been published by 60 different first authors from more than 20 countries. ZEISS AT LISA tri family prove to deliver high visual quality to patients worldwide, regardless of their origin.
Numerous peer-reviewed publications investigated patient-reported outcomes after ZEISS AT LISA tri IOL implantation. Repeatedly, surgeons confirmed high patient satisfaction, further proving the excellent performance of the reference trifocal technology.
Explore the benefits and technical specifications of the ZEISS AT LISA tri family in more depth.